No Data
No Data
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
H.C. Wainwright Maintains EyePoint Pharmaceuticals(EYPT.US) With Buy Rating, Maintains Target Price $22
EyePoint Pharmaceuticals Price Target Maintained With a $22.00/Share by HC Wainwright & Co.
EyePoint Pharmaceuticals Analyst Ratings
Express News | EyePoint Pharmaceuticals Inc - Topline Data for Phase 3 Pivotal Program Expected in 2026
Express News | EyePoint Announces First Patient Dosed in Second Global Phase 3 Lucia Clinical Trial of Duravyu™ for the Treatment of Wet Age-Related Macular Degeneration
Unlock the Full List